COMPARISON OF FE-HBED AND FE-EHPG AS HEPATOBILIARY MR CONTRAST AGENTS

被引：20

作者：

HOENER, BA ^{[1
]}

ENGELSTAD, BL ^{[1
]}

RAMOS, EC ^{[1
]}

MACAPINLAC, HA ^{[1
]}

PRICE, DC ^{[1
]}

JOHNSON, TR ^{[1
]}

WHITE, DL ^{[1
]}

机构：

[1] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT RADIOL,CONTRAST MEDIA LAB,SAN FRANCISCO,CA 94143

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1991年 / 1卷 / 03期

关键词：

BILE DUCTS; MR STUDIES; 76.1214; CONTRAST ENHANCEMENT; CONTRAST MEDIA; COMPARATIVE STUDIES; EFFECTS; EXPERIMENTAL STUDIES; IRON; LIVER; 761.1214;

D O I：

10.1002/jmri.1880010314

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The authors studied the biodisposition and hepatobiliary transport of two potential magnetic resonance imaging contrast agents, the iron (III) chelates of N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED) and diastereomeric N,N'-ethylenebis(2-hydroxyphenylglycine) (EHPG). Fecal and urinary excretion (mean +/- standard deviation), respectively, of FE-59 over 7 days in rats given tracer doses of the contrast agents were 67% +/- 2% and 22% +/- 1% for Fe-59-HBED and 22% +/- 2% and 26% +/- 5% for Fe-59-EHPG. In bile duct-cannulated rats given 0.05-mmol/kg doses labeled with Fe-59, 52% +/-8% of Fe-59 from Fe-59-HBED but only 17% +/-3% of that from Fe-59-EHPG was excreted into the bile within 90 minutes. Bromosulfophthalein, but not taurocholate or oxyphenonium. was shown to compete with both agents for hepatobiliary transport. Enterohepatic recirculation of both agents was less than 1%.

引用

页码：357 / 362

页数：6

共 14 条

[1]

Martell AE, The design and synthesis of chelating agents, Development of iron chelators for clinical use, pp. 67-131, (1980)

[2]

Smith RM, Martell AE, Critical stability constants, 3, (1975)

[3]

Pitt CG, Gupta G, Estes WE, Et al., The selection and evaluation of new chelating agents for the treatment of iron overload, J Pharm Exp Ther, 208, pp. 12-18, (1979)

[4]

Grady RW, Jacobs A, The screening of potential iron chelating drugs, Development of iron chelators for clinical use, pp. 133-164, (1980)

[5]

Haddock EP, Zapolski EJ, Rubin M, Princiotto JV, Biliary excretion of chelated iron, Experimental Biology and Medicine, 120, pp. 663-668, (1965)

[6]

Bagley DH, Zapolski EJ, Rubin M, Princiotto JV, The metabolism and placental transfer of oral and parenteral iron chelates, Clin Chim Acta, 35, pp. 311-315, (1971)

[7]

Lauffer RB, Grief WL, Stark DD, Et al., Iron‐EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies, J Comput Assist Tomogr, 9, pp. 431-438, (1985)

[8]

Engelstad BL, White DL, Ramos EC, Johnson TR, Macapinlac HA, Moseley ME, In vivo comparison of iron complexes exhibiting hepatobiliary enhancement in MRI (abstr), Book of abstracts: Society of Magnetic Resonance in Medicine 1986, pp. 1506-1507, (1986)

[9]

Shtern F, Garrido L, Compton C, Et al., MR imaging of liver tumors in mice: contrast enhancement with Fe(EHPG) (abstr), Society of Magnetic Resonance in Medicine 1987, (1987)

[10]

Klaassen CD, Watkins JB, Mechanisms of bile formation, hepatic uptake, and biliary excretion, Pharm Rev, 36, pp. 1-67, (1984)

← 1 2 →